Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 1
2001 1
2002 2
2003 2
2004 4
2006 1
2007 1
2009 2
2010 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors.
Hammond M, Washburn DG, Hoang HT, Manns S, Frazee JS, Nakamura H, Patterson JR, Trizna W, Wu C, Azzarano LM, Nagilla R, Nord M, Trejo R, Head MS, Zhao B, Smallwood AM, Hightower K, Laping NJ, Schnackenberg CG, Thompson SK. Hammond M, et al. Among authors: azzarano lm. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4441-5. doi: 10.1016/j.bmcl.2009.05.051. Epub 2009 May 18. Bioorg Med Chem Lett. 2009. PMID: 19497745
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Miller WH, Manley PJ, Cousins RD, Erhard KF, Heerding DA, Kwon C, Ross ST, Samanen JM, Takata DT, Uzinskas IN, Yuan CC, Haltiwanger RC, Gress CJ, Lark MW, Hwang SM, James IE, Rieman DJ, Willette RN, Yue TL, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF. Miller WH, et al. Among authors: azzarano lm. Bioorg Med Chem Lett. 2003 Apr 17;13(8):1483-6. doi: 10.1016/s0960-894x(03)00102-1. Bioorg Med Chem Lett. 2003. PMID: 12668017
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Miller WH, Bondinell WE, Cousins RD, Erhard KF, Jakas DR, Keenan RM, Ku TW, Newlander KA, Ross ST, Haltiwanger RC, Bradbeer J, Drake FH, Gowen M, Hoffman SJ, Hwang SM, James IE, Lark MW, Lechowska B, Rieman DJ, Stroup GB, Vasko-Moser JA, Zembryki DL, Azzarano LM, Adams PC, Huffman WF, et al. Miller WH, et al. Among authors: azzarano lm. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12. doi: 10.1016/s0960-894x(99)00283-8. Bioorg Med Chem Lett. 1999. PMID: 10406646
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.
Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan CC, Haltiwanger RC, Gowen M, Hwang SM, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF. Miller WH, et al. Among authors: azzarano lm. J Med Chem. 2000 Jan 13;43(1):22-6. doi: 10.1021/jm990446u. J Med Chem. 2000. PMID: 10633035 No abstract available.
Improving the developability profile of pyrrolidine progesterone receptor partial agonists.
Kallander LS, Washburn DG, Hoang TH, Frazee JS, Stoy P, Johnson L, Lu Q, Hammond M, Barton LS, Patterson JR, Azzarano LM, Nagilla R, Madauss KP, Williams SP, Stewart EL, Duraiswami C, Grygielko ET, Xu X, Laping NJ, Bray JD, Thompson SK. Kallander LS, et al. Among authors: azzarano lm. Bioorg Med Chem Lett. 2010 Jan 1;20(1):371-4. doi: 10.1016/j.bmcl.2009.10.092. Epub 2009 Oct 25. Bioorg Med Chem Lett. 2010. PMID: 19926282
Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
Ward KW, Azzarano LM. Ward KW, et al. Among authors: azzarano lm. J Pharmacol Exp Ther. 2004 Aug;310(2):703-9. doi: 10.1124/jpet.104.068288. Epub 2004 Mar 31. J Pharmacol Exp Ther. 2004. PMID: 15056727
15 results